Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Recombinant Exendin-4 Formulations in Healthy Chinese Males
NCT03199261Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2016
- Primary completion
- Jan 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Bioequivalency between the 2 formulations of rE-4 at 8 hours. Started Dec 2016; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03199261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199261.